Skip to main content
. 2022 Jul 18;20:3833–3838. doi: 10.1016/j.csbj.2022.07.026

Fig. 3.

Fig. 3

Validation of the top 10 sgRNAs of ICAM-1. A. Indel frequencies of the top 10 ICAM-1 sgRNAs, determined byTIDE analysis. B. Cell viability of ICAM-1 knockout cells upon RV challenge, in comparison with non-targeting sgRNA-treated cells. C-D. Viral loads in medium supernatant (C) or cell lysates (D) of non-targeting sgRNA-treated and ICAM-1 knockout cells after RV challenge. Viral RNA in cell lysates is normalized to RPLP0 expression. The significance of difference between ICAM-1 knockout and non-targeting sgRNA-treated cells are determined using two-tailed, unpaired Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ***, P < 0.0001.